Press Release

Press Release

RepliCel Retains Westwicke Partners as Investor Relations Counsel

VANCOUVER, BC – September 4, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies, today announced that it has retained Westwicke Partners as its investor relations agency to assist in the company’s communications with investors. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector.

“Westwicke Partners’ expertise, established relationships and strategic counsel in investor relations and the biopharmaceutical sector will add significant value to RepliCel’s outreach efforts to increase visibility within the financial and investor communities,” stated David Hall, CEO of RepliCel. “We look forward to working with the Westwicke team and to leveraging their experience as we continue to advance our clinical development programs.”

About RepliCel Life Sciences
RepliCel is a clinical stage biopharmaceutical company focused on developing autologous cell therapies. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic alopecia (pattern baldness). Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. RepliCel Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon injuries. Both product candidates are based on RepliCel’s innovative technology which utilizes cells isolated from a patient’s own healthy hair follicles to address specific cellular deficits. Phase II clinical trials, for both programs, are planned for the later part of 2013. For additional information please visit

About Westwicke Partners
Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to healthcare companies. With offices in Baltimore, San Francisco and San Diego, the firm works with over 50 public and private companies across all subsectors of healthcare. Services provided by Westwicke include corporate message and positioning, investor presentation review, sell side relationship building, buy side targeting, earnings call preparation, capital markets advisory, pre-IPO planning and execution, and investor day meetings. All of Westwicke’s senior professionals have extensive Wall Street experience as former sell side and buy side research analysts, portfolio managers, investment bankers, institutional sales people, and equity capital markets professionals. The firm works with its clients to help position their story properly within the investment community, raise their visibility on Wall Street, and develop value-added strategies to build a quality, long-term shareholder base and enhance equity market value. For additional information about Westwicke please visit

Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements that relate to the approval and commercialization of the Company’s hair restoration process, the Company’s development of its Achilles tendon technology and the expected commencement of the Company’s Phase II clinical trial for its tendon technology. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2012 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at and with the British Columbia Securities Commission on Sedar at

Tammey George
Director of Communications
RepliCel Life Sciences

Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507

Robert H. Uhl
Managing Director
(858) 356-5932

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.